Zacks Investment Research upgraded shares of CONATUS PHARMA (CNAT) from NEUTRAL to OUTPERFORM on October 14, 2014, with a target price of $7.20.
Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CONATUS PHARMA (CNAT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment